BioFactura

Executive Summary

BioFactura is a clinical-stage biopharmaceutical company specializing in the development and manufacturing of biosimilars, biodefense medical countermeasures, and novel biologics. Leveraging its proprietary StableFast™ Biomanufacturing Platform, the company aims to accelerate and enhance the production of biologic medicines, targeting autoimmune diseases, infectious diseases, cancer, and national security threats such as smallpox and Ebola. Founded in 2005 and headquartered in Frederick, Maryland, BioFactura operates as a private entity. While the company has not disclosed total funding or valuation, its focus on high-value biosimilars and biodefense positions it within niche markets with significant unmet needs. However, as a private Phase 1 company with no disclosed pipeline details, its near-term prospects depend heavily on securing partnerships or government contracts to advance its programs.

Upcoming Catalysts (preview)

• Q4 2026Government Biodefense Contract Award60% success
• Q1 2027Lead Biosimilar Candidate Phase 2 Initiation40% success
• Q2 2027Strategic Partnership or Licensing Deal50% success